KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Gains from Investment Securities: 2015-2025

Historic Gains from Investment Securities for Astrana Health (ASTH) over the last 10 years, with Q3 2025 value amounting to $670000.0.

  • Astrana Health's Gains from Investment Securities fell 8812.48% to $670000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 2582.77%. This contributed to the annual value of $388545.0 for FY2024, which is 2294.46% down from last year.
  • Latest data reveals that Astrana Health reported Gains from Investment Securities of $670000.0 as of Q3 2025, which was down 8812.48% from $1.4 million recorded in Q2 2025.
  • Astrana Health's Gains from Investment Securities' 5-year high stood at $18.5 million during Q4 2023, with a 5-year trough of $27000.0 in Q1 2021.
  • Its 5-year average for Gains from Investment Securities is $2.5 million, with a median of $398000.0 in 2022.
  • As far as peak fluctuations go, Astrana Health's Gains from Investment Securities tumbled by 9748.65% in 2021, and later soared by 1858484.85% in 2023.
  • Astrana Health's Gains from Investment Securities (Quarter) stood at $238000.0 in 2021, then tumbled by 58.4% to $99000.0 in 2022, then soared by 18584.85% to $18.5 million in 2023, then plummeted by 95.6% to $814000.0 in 2024, then decreased by 17.69% to $670000.0 in 2025.
  • Its Gains from Investment Securities stands at $670000.0 for Q3 2025, versus $1.4 million for Q2 2025 and $5.7 million for Q1 2025.